Targeting TGFβ signaling for cancer therapy

Sravisht Iyer, Zhen Guo Wang, Mojtaba Akhtari, Wenli Zhao, Prem Seth

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Transforming growth factor (TGF) βs are multifunctional polypeptides that regulate several cellular functions, including cell growth and differentiation, extra cellular matrix production, motility and immunosuppression. The growth-inhibiting properties of TGFβ have gained much attention into its role as a tumor suppressor. There is, however, now increasing evidence that TGFβ switches roles, from tumor suppressor to tumor promoter, as the tumor progresses. Given the integral role of TGFβ in the tumor progression, it follows that TGFβ signaling offers an attractive target for cancer therapy. Several strategies including the use of antisense oligonucleotides for TGFβ, TGFβ antibodies, dominant negative TGFβ receptor II, and small drug-molecules to inhibit TGFβ receptor I kinase have shown great promise in the preclinical studies. These new findings, coupled with progressing clinical trials indicate that inhibition of TGFβ signaling may, indeed, be a viable option to cancer therapy. This review summarizes the TGFβ signaling, the dual role of TGFβ - as a tumor suppressor and tumor promoter, and various strategies targeted against TGFβ signaling for cancer therapy. The next few years promise to better our understanding of approaching cancer therapy with an eye to the inhibition of TGFβ signaling.

Original languageEnglish (US)
Pages (from-to)261-266
Number of pages6
JournalCancer Biology and Therapy
Volume4
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Transforming Growth Factors
Neoplasms
Therapeutics
Growth Factor Receptors
Carcinogens
Antisense Oligonucleotides
Growth
Immunosuppression
Cell Differentiation
Phosphotransferases

Keywords

  • Animal models
  • Breast cancer
  • Cancer therapy
  • Clinical trials
  • Colon cancer
  • Gene therapy
  • Metastasis
  • Prostate cancer
  • TGFβ
  • TGFβ receptor

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Iyer, S., Wang, Z. G., Akhtari, M., Zhao, W., & Seth, P. (2005). Targeting TGFβ signaling for cancer therapy. Cancer Biology and Therapy, 4(3), 261-266. https://doi.org/10.4161/cbt.4.3.1566

Targeting TGFβ signaling for cancer therapy. / Iyer, Sravisht; Wang, Zhen Guo; Akhtari, Mojtaba; Zhao, Wenli; Seth, Prem.

In: Cancer Biology and Therapy, Vol. 4, No. 3, 03.2005, p. 261-266.

Research output: Contribution to journalReview article

Iyer, S, Wang, ZG, Akhtari, M, Zhao, W & Seth, P 2005, 'Targeting TGFβ signaling for cancer therapy', Cancer Biology and Therapy, vol. 4, no. 3, pp. 261-266. https://doi.org/10.4161/cbt.4.3.1566
Iyer S, Wang ZG, Akhtari M, Zhao W, Seth P. Targeting TGFβ signaling for cancer therapy. Cancer Biology and Therapy. 2005 Mar;4(3):261-266. https://doi.org/10.4161/cbt.4.3.1566
Iyer, Sravisht ; Wang, Zhen Guo ; Akhtari, Mojtaba ; Zhao, Wenli ; Seth, Prem. / Targeting TGFβ signaling for cancer therapy. In: Cancer Biology and Therapy. 2005 ; Vol. 4, No. 3. pp. 261-266.
@article{8be5a71f486e4e77a1aab83016cb1122,
title = "Targeting TGFβ signaling for cancer therapy",
abstract = "Transforming growth factor (TGF) βs are multifunctional polypeptides that regulate several cellular functions, including cell growth and differentiation, extra cellular matrix production, motility and immunosuppression. The growth-inhibiting properties of TGFβ have gained much attention into its role as a tumor suppressor. There is, however, now increasing evidence that TGFβ switches roles, from tumor suppressor to tumor promoter, as the tumor progresses. Given the integral role of TGFβ in the tumor progression, it follows that TGFβ signaling offers an attractive target for cancer therapy. Several strategies including the use of antisense oligonucleotides for TGFβ, TGFβ antibodies, dominant negative TGFβ receptor II, and small drug-molecules to inhibit TGFβ receptor I kinase have shown great promise in the preclinical studies. These new findings, coupled with progressing clinical trials indicate that inhibition of TGFβ signaling may, indeed, be a viable option to cancer therapy. This review summarizes the TGFβ signaling, the dual role of TGFβ - as a tumor suppressor and tumor promoter, and various strategies targeted against TGFβ signaling for cancer therapy. The next few years promise to better our understanding of approaching cancer therapy with an eye to the inhibition of TGFβ signaling.",
keywords = "Animal models, Breast cancer, Cancer therapy, Clinical trials, Colon cancer, Gene therapy, Metastasis, Prostate cancer, TGFβ, TGFβ receptor",
author = "Sravisht Iyer and Wang, {Zhen Guo} and Mojtaba Akhtari and Wenli Zhao and Prem Seth",
year = "2005",
month = "3",
doi = "10.4161/cbt.4.3.1566",
language = "English (US)",
volume = "4",
pages = "261--266",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Targeting TGFβ signaling for cancer therapy

AU - Iyer, Sravisht

AU - Wang, Zhen Guo

AU - Akhtari, Mojtaba

AU - Zhao, Wenli

AU - Seth, Prem

PY - 2005/3

Y1 - 2005/3

N2 - Transforming growth factor (TGF) βs are multifunctional polypeptides that regulate several cellular functions, including cell growth and differentiation, extra cellular matrix production, motility and immunosuppression. The growth-inhibiting properties of TGFβ have gained much attention into its role as a tumor suppressor. There is, however, now increasing evidence that TGFβ switches roles, from tumor suppressor to tumor promoter, as the tumor progresses. Given the integral role of TGFβ in the tumor progression, it follows that TGFβ signaling offers an attractive target for cancer therapy. Several strategies including the use of antisense oligonucleotides for TGFβ, TGFβ antibodies, dominant negative TGFβ receptor II, and small drug-molecules to inhibit TGFβ receptor I kinase have shown great promise in the preclinical studies. These new findings, coupled with progressing clinical trials indicate that inhibition of TGFβ signaling may, indeed, be a viable option to cancer therapy. This review summarizes the TGFβ signaling, the dual role of TGFβ - as a tumor suppressor and tumor promoter, and various strategies targeted against TGFβ signaling for cancer therapy. The next few years promise to better our understanding of approaching cancer therapy with an eye to the inhibition of TGFβ signaling.

AB - Transforming growth factor (TGF) βs are multifunctional polypeptides that regulate several cellular functions, including cell growth and differentiation, extra cellular matrix production, motility and immunosuppression. The growth-inhibiting properties of TGFβ have gained much attention into its role as a tumor suppressor. There is, however, now increasing evidence that TGFβ switches roles, from tumor suppressor to tumor promoter, as the tumor progresses. Given the integral role of TGFβ in the tumor progression, it follows that TGFβ signaling offers an attractive target for cancer therapy. Several strategies including the use of antisense oligonucleotides for TGFβ, TGFβ antibodies, dominant negative TGFβ receptor II, and small drug-molecules to inhibit TGFβ receptor I kinase have shown great promise in the preclinical studies. These new findings, coupled with progressing clinical trials indicate that inhibition of TGFβ signaling may, indeed, be a viable option to cancer therapy. This review summarizes the TGFβ signaling, the dual role of TGFβ - as a tumor suppressor and tumor promoter, and various strategies targeted against TGFβ signaling for cancer therapy. The next few years promise to better our understanding of approaching cancer therapy with an eye to the inhibition of TGFβ signaling.

KW - Animal models

KW - Breast cancer

KW - Cancer therapy

KW - Clinical trials

KW - Colon cancer

KW - Gene therapy

KW - Metastasis

KW - Prostate cancer

KW - TGFβ

KW - TGFβ receptor

UR - http://www.scopus.com/inward/record.url?scp=25444515482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444515482&partnerID=8YFLogxK

U2 - 10.4161/cbt.4.3.1566

DO - 10.4161/cbt.4.3.1566

M3 - Review article

C2 - 15846079

AN - SCOPUS:25444515482

VL - 4

SP - 261

EP - 266

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -